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ABSTRACT 
 
Background: Aldosterone plays a key role in the pathophysiology of heart 
failure. In around 50% of such patients, aldosterone ‘escapes’ from inhibition 
by drugs that interrupt the renin-angiotensin axis; such patients have a worse 
clinical outcome.  Insulin resistance is a risk factor in heart failure and 
cardiovascular disease. The relationship between aldosterone status and 
insulin sensitivity was investigated in a cohort of heart failure patients.  
Methods: 302 patients with New York Heart Association (NYHA) class II-IV 
heart failure on conventional therapy were randomized in ALiskiren 
Observation of heart Failure Treatment study (ALOFT), designed to test the 
safety of a directly acting renin inhibitor. Plasma aldosterone and 24-hour 
urinary aldosterone excretion as well as fasting insulin and Homeostasis 
model assessment of insulin resistance (HOMA-IR) were measured. Subjects 
with aldosterone escape and high urinary aldosterone were identified 
according to previously accepted definitions.  
Results: Twenty per-cent of subjects demonstrated aldosterone escape and 
34% had high urinary aldosterone levels. At baseline, there was a positive 
correlation between fasting insulin and plasma(r=0.22 p<0.01) and urinary 
aldosterone(r=0.19 p<0.03). Aldosterone escape and high urinary aldosterone 
subjects both demonstrated higher levels of fasting insulin (p<0.008, p<0.03), 
HOMA-IR (p<0.06, p<0.03) and insulin-glucose ratios (p<0.006, p<0.06) when 
compared to low aldosterone counterparts. All associations remained 
significant when adjusted for potential confounders. 
Conclusions: This study demonstrates a novel direct relationship between 
aldosterone status and insulin resistance in heart failure. This observation 
merits further study and may identify an additional mechanism that contributes 
to the adverse clinical outcome associated with aldosterone escape.  
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INTRODUCTION 
 
The mineralocorticoid hormone, aldosterone, plays an important role in 
development and outcome of cardiovascular disease. Relative excess of 
aldosterone, as defined by a raised ratio of aldosterone to renin (ARR), is 
found in approximately 10% of subjects with hypertension and up to 20% of 
cases of resistant hypertension(1).  Patients with Primary Aldosteronism (PA) 
also have worse cardiovascular outcomes than those with essential 
hypertension(2) while aldosterone levels after myocardial infarction are good 
predictors of a range of adverse outcomes. Finally, whilst it is well recognised 
that aldosterone plays a key role in the aetiology and progression of heart 
failure, more recent evidence suggests a role in the development of left 
ventricular fibrosis (independent of blood pressure effects)(3) as well as its 
contribution to cardiac remodelling after myocardial infarction(4).  
In patients treated for heart failure using conventional therapy, the concept of 
‘aldosterone escape’ (or breakthrough) is well recognised. This describes the 
failure of suppression of plasma aldosterone levels despite treatment with 
angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor 
blockers (ARB), both of which should inhibit aldosterone production(5). The 
incidence of this phenomenon in heart failure is variable, with estimates 
ranging from 10-51%, mainly due to a lack of consensus in the definition of 
aldosterone escape(6).  However, it is accepted that aldosterone escape is 
associated with poor clinical outcome; studies have shown that heart failure 
patients with aldosterone escape tend to demonstrate higher LV mass, 
decreased arterial compliance, reduced exercise capacity and a more rapid 
decline in renal function than patients in whom aldosterone levels remain 
suppressed with treatment(6). The mechanism of aldosterone escape in heart 
failure is likely to be multifactorial, and may reflect the importance of trophins 
other than angiotensin II, including plasma potassium, in the regulation of 
aldosterone production. 
While much of the focus on the adverse cardiovascular consequences of 
aldosterone has been on vascular structure and function, it is clear that the 
hormone has important metabolic effects that may also influence 
cardiovascular risk(7). In particular, there is evidence of an association 
between aldosterone and insulin resistance and risk of diabetes. For example, 
the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 
recently named PA as a potential cause of diabetes per se(8). Overall, the 
majority of clinical studies report that PA patients have higher rates of 
impaired glucose tolerance than essential hypertensives, but it is unclear 
whether this is due to insulin resistance or impaired insulin release; 
nonetheless, insulin resistance is reversed by amelioration of aldosterone 
excess(9;10). 
Insulin resistance occurs in up to 50% of hypertensive subjects and is 
associated with a 2-5 fold increased risk of CV mortality(11). Insulin 
resistance is also common in patients with heart failure; the prevalence of 
type 2 diabetes mellitus in heart failure patients is 6-25% and higher if 
symptomatic heart failure(12). Diabetes mellitus increases the risk of 
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hospitalisation in heart failure and is an independent predictor of mortality in 
population studies (12).  
Thus, while aldosterone and insulin resistance both contribute to the 
pathophysiology and adverse outcome associated with heart failure, the 
relationship between these biochemical parameters in heart failure remains 
unclear. This was explored within a stable heart failure population from the 
ALiskiren Observation of heart Failure Treatment (ALOFT) study, designed to 
assess the safety and tolerability of the new direct renin inhibitor, Aliskiren. In 
particular, as heart failure patients with aldosterone escape have a less good 
prognosis, we wished to determine whether these subjects also have a 
greater degree of insulin resistance.   
 
METHODS 
 
Recruitment details and procedures have been described elsewhere (13). 
Briefly, the ALOFT study randomised 302 patients with New York Heart 
Association (NYHA) class II-IV heart failure treated with either ACE inhibitor or 
ARB and beta-blocker (in 95%) to either treatment with aliskiren or placebo. 
For the purposes of this report, subjects taking mineralocorticoid receptor 
blockers (n=101) were excluded from further analysis.  
At the initial baseline visit, 186 subjects underwent 24 hour urine collection for 
measurement of aldosterone, total protein and sodium excretion.  Additionally, 
early morning fasting plasma samples were taken from subjects (supine) for 
plasma glucose, glycosylated haemoglobin (HbA1c), HOMA-IR (fasting insulin 
(mU/ml) x fasting plasma glucose (mmol/l)/22.5 as previously described(14)) 
as well as aldosterone, plasma renin activity (PRA) and plasma renin 
concentration (PRC). 
As all patients had been on a stable dose of ACE inhibitor or ARB for at least 
4 weeks prior to analysis, we used a plasma aldosterone cut-off level of > 
144pg/ml to define plasma aldosterone escape in keeping with previous 
studies(15). Twenty four hour urinary aldosterone level of >12micrograms/24 
hours was used to define ‘high’ urinary aldosterone again in agreement with 
previous studies and with well recognised criteria for the diagnosis of Primary 
Aldosteronism (PA)(16).   
As not all biochemical data were normally distributed, non-parametric 
methods of analysis were used to directly compare markers of insulin 
sensitivity according to aldosterone status (Mann-Whitney test using Minitab, 
state college PA, version 14). Adjustment for potential confounders (age, sex, 
body mass index, diabetes status and blood pressure) was performed using 
binary logistic regression. A p-value <0.05 was deemed significant.  
 
RESULTS 
 
General 
Summary statistics of the subjects subdivided according to plasma and 
urinary aldosterone levels are demonstrated in Table I. Of the patients 
studied, 20% (37) demonstrated aldosterone escape and 34% (63) had high 
urinary aldosterone excretion. There was some overlap between these two 
groups with 26 subjects demonstrating aldosterone escape in both urine and 
plasma. 
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Aldosterone levels positively correlated with fasting plasma insulin at baseline. 
This was seen with both plasma aldosterone (r=0.216, p<0.01; Figure 1) and 
urinary aldosterone excretion rates (r=0.188, p<0.03). 
(a) 
 
 Aldosterone 
escape (n=37) 
No aldosterone 
escape (n=150) 
p value 
Sex 5 female 28 female  
Age (y) 67 (61-75) 72 (65-77.2) 0.155 
SBP (mm/Hg) 125.3 (119.3-132) 130 (121.1-132) 0.023 
DBP(mm/Hg) 77.3 (70-80.3) 78.2 (72.8-81.4) 0.481 
BMI 26.6 (24.4-28.5) 27 (24.9-29.6) 0.51 
Plasma aldosterone 
(pg/ml) 
202 (163.3-232.2) 55.4 (12.4-85) <0.00001 
Urinary aldosterone 
(mcg/24h) 
17.37 (11.9-23.8) 6.82 (3.1-12) <0.0001 
LVEF (%) 31.9 (26-34.7) 30.9 (28.1-34.5) 0.5519 
Number (%) with 
diabetes 
18 (49) 51 (34) 0.09 
 
(b) 
 
 High UAldo (n=63) Low UAldo 
(n=123) 
p value 
Sex 11 female 22 female  
Age (y) 69 (63-76) 72 (64-76) 0.561 
SBP(mm/Hg) 125.33 (120-134.7) 130.67 (120-145) 0.01 
DBP(mm/Hg) 77.33 (73-80) 78.33 (71.7-82.3) 0.7823 
BMI 27.1 (25.1-29) 26.9 (24.5-29.7) 0.999 
Plasma aldosterone 
(pg/ml) 
112.86 (60.1-209.3) 56.88 (15.5-89.7) <0.00001 
Urinary aldosterone 
(mcg/24h) 
19.19 (15.8-39) 5.8 (2.63-8.14) <0.0001 
LVEF (%) 32.2 (28.2-34.9) 30.6 (27.2-33.9) 0.498 
Number (%) with 
diabetes 
29 (46) 41 (33) 0.09 
Table I. Summary characteristics (medians (+inter-quartile range)) of ALOFT 
subjects subdivided according to (a) plasma and (b) urinary aldosterone 
levels. 
Data were compared by Mann-Whitney testing. 
SBP:systolic blood pressure, DBP:diastolic blood pressure, BMI: body mass 
index, LVEF: left ventricular ejection fraction 
 
 
Insulin sensitivity and aldosterone status 
Subjects on insulin (n=23) were excluded from this analysis. Early morning 
fasting insulin was significantly higher in aldosterone escape and high urinary 
aldosterone groups in comparison to subjects without aldosterone escape and 
lower levels of urinary aldosterone excretion (Figure 2). This relationship was 
 on 5 November 2009 heart.bmj.comDownloaded from 
 6
consistent using other markers of insulin sensitivity; HOMA-IR levels and 
insulin-glucose ratios (IGR) were higher in aldosterone escape and high 
urinary aldosterone cohorts (Figure 2). Patients who demonstrated both high 
plasma and urinary aldosterone levels were most insulin resistant (p<0.01, 
data not shown). All relationships remained significant when adjusted for 
potential confounders known to influence insulin resistance (age/sex/blood 
pressure/BMI).  
When plasma and urinary aldosterone levels were divided into tertiles, it was 
found that, as plasma levels of aldosterone increased, fasting insulin also 
increased (Figure 3) as well as HOMA-IR (p<0.007) and IGR (p<0.0001).  
 
Diabetes Status 
Patients with non-insulin treated diabetes were not excluded from this study. 
This was because exclusion of diabetics resulted in a substantial reduction in 
subject numbers particularly in the aldosterone excess groups and a loss of 
study power meaning that although there was still a tendency to increased 
insulin resistance in the aldosterone excess groups, this did not always reach 
statistical significance. Additionally, there was a trend to higher prevalence of 
both diabetes and insulin use in subjects with biochemical evidence of 
aldosterone excess although again this did not reach statistical significance 
(Table II). However, the presence of diabetes were incorporated into binary 
logistic regression analysis and the relationships between insulin resistance 
and biochemical aldosterone excess remained significant (p<0.008 
aldosterone escape and insulin, p<0.03 high urinary aldosterone and insulin).  
 
 
Cohort Diabetes p value Insulin 
Aldosterone escape 18 (49%)  
<0.09 
4 (11%) 
No aldosterone 
escape 
51 (34%) 9 (6%) 
High urinary 
aldosterone 
29 (46%)  
<0.09 
6 (9.5%) 
Low urinary 
aldosterone 
41 (33%) 5 (4%) 
Table II. Prevalence of diabetes status and insulin use in cohort stratified 
according to plasma and urinary aldosterone status. 
 
 
DISCUSSION 
 
These data demonstrate in a stable heart failure population that subjects with 
relative aldosterone excess have evidence of increased insulin resistance, a 
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relationship which persists after correction for diabetes status. In addition, 
there is a trend to an increased prevalence of diabetes in the high aldosterone 
subjects although this does not reach statistical significance. 
 High aldosterone levels and insulin resistance are both associated, 
independently, with greater risk of cardiovascular disease and heart failure. 
Subjects with hypertension and aldosterone excess have an excess of 
adverse vascular events (particularly stroke) when compared to subjects with 
equivalent essential hypertension(2). It is noteworthy that that serum levels of 
aldosterone (and the glucocorticoid hormone, cortisol) have recently been 
shown to be independent predictors of increased mortality risk in patients with 
chronic heart failure (17) while the role of aldosterone in heart failure has 
been highlighted by large scale clinical trials demonstrating additional benefit 
of mineralocorticoid blockade in conjunction with conventional therapy(5).  
Aldosterone levels are positively correlated with poor outcome after 
myocardial infarction, including increased risk of death, cardiac arrest, 
dysryhthmia. An association between essential hypertension and insulin 
resistance is also supported by a large body of evidence and is consistent 
with the notion that insulin resistant subjects have greater long term 
cardiovascular risk(18-20).  
Insulin resistance is associated with vascular endothelial dysfunction and, in 
particular, with reduced availability of endothelial nitric oxide(21); it is possible 
that this contributes to the associated increased risk of cardiovascular events 
in patients with hypertension and insulin resistance. Insulin resistance is 
independently associated with risk of heart failure and adverse outcome in 
that circumstance(12). However, despite the associations between 
aldosterone and insulin resistance in cardiovascular disease, the nature and 
potential mechanism of the relationship between the two remains unclear. In a 
large prospective study, Catena et al. demonstrated that patients with PA 
were more insulin resistant that normotensive controls and that medical or 
surgical treatment of the aldosterone excess improved insulin sensitivity(9). 
Nevertheless, PA subjects were less insulin resistant than those with essential 
hypertension. The same group subsequently demonstrated that plasma 
aldosterone levels correlated with markers of insulin resistance and 
hyperinsulinaemia in hypertensive patients(22). Indeed, the majority of clinical 
evidence supports an association between aldosterone excess and increased 
insulin resistance in hypertension although there are conflicting reports as to 
whether this is a stronger(23) or weaker (9) association than in essential 
hypertension. 
Our data suggest a positive correlation between aldosterone and insulin 
resistance in heart failure.  This finding is consistent with other observational 
findings. Thus, chronic heart failure and diabetes often co-exist, an 
association noted in the Framingham Study where 19% of patients with 
chronic heart failure had diabetes; the risk of heart failure increased 2-8 fold in 
the presence of diabetes(24). This relationship between chronic heart failure 
and diabetes may also extend to insulin resistance. In one large prospective 
study of 1187 elderly men there was a clear inverse relationship between the 
risk of heart failure and insulin sensitivity and there are other groups who have 
confirmed such an observation(25). This notion is further supported by recent 
evidence from the CHARM study illustrating that, in heart failure patients, 
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glycosylated haemoglobin A1c (HbA1c) is an independent predictor of 
morbidity and mortality(26). 
The mechanism of the link between aldosterone and insulin resistance 
remains unclear. It is, of course, possible that the association is not causal; 
subjects with more severe heart failure (who may be more likely to be insulin 
resistant) may have greater activation of the neuroendocrine system and, 
consequently, higher aldosterone levels.  Alternatively, it is possible that 
insulin resistance, which in its early stages is associated with 
hyperinsulinaemia, might directly lead to increased aldosterone production.  
This seems plausible as we observed a positive correlation between plasma 
insulin and aldosterone and so a possible explanation is that activation of the 
RAAS contributes directly to insulin resistance.  An association between 
insulin resistance and the renin-angiotensin-aldosterone system has recently 
been strengthened by several large scale clinical trials which demonstrate that 
blockade of the RAAS with ACE inhibitors or angiotensin receptor blockers 
results in a reduction in new cases of diabetes mellitus(27). However, this link 
remains controversial with a recent robust clinical trial failing to show a 
significant effect of ramipril on the subsequent development of diabetes in 
subjects with impaired glucose tolerance or impaired fasting glucose(28).   
A simple haemodynamic explanation linking the RAAS to the development of 
insulin resistance is possible, where increased angiotensin II and aldosterone 
levels may be associated with reduced blood flow to skeletal muscle and, as a 
result, diminished tissue glucose uptake(29). However, there is controversy 
about the contribution of flow to the efficiency of glucose extraction and more 
direct effects on insulin release and action seem more likely. This is supported 
by work by Mosso et al who demonstrated that impaired glucose metabolism 
in PA patients was associated with decreased markers of pancreatic beta cell 
function (C-peptide and HOMA-βF) which improved in response to 
spironolactone treatment(30). Another potential mechanism is aldosterone-
induced electrolyte abnormalities-hypokalaemia is known to alter insulin 
secretion and modulate insulin receptor function(31) and recent in vitro 
experiments on isolated pancreatic islets suggest that extracellular potassium 
stimulates insulin secretion(32).In addition, magnesium deficiency can also 
reduce insulin production and magnesium supplementation prevents diabetes 
in rat models(33).  Finally, mineralocorticoid receptors are present on 
adipoctyes and their activation affects insulin signalling and adipocytokine 
release(34). Subsequent experiments have demonstrated that adipocytokines 
can stimulate production of adrenal corticosteroids in vitro(35). These effects 
may directly alter tissue insulin sensitivity, and offer a plausible direct 
association between aldosterone, insulin resistance and obesity(36).  
Limitations of this study are mainly those imposed as a result of post-hoc 
analysis of data where the primary outcome was not to examine the 
relationship between aldosterone and insulin status. In addition, diabetic 
subjects would, ideally, not have been included in this study but were included 
to provide sufficient study power. However diabetes status and insulin use 
were incorporated into a binary logistic regression model of aldosterone and 
insulin resistance and did not alter these relationships. The final limitation is 
our use of simple indirect measurements of insulin sensitivity which, although 
robust and in common clinical use, are less sensitive than the gold standard 
measure of insulin sensitivity, the euglycaemic-hyperinsulinaemic glucose 
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clamp. Strengths of the study include the fact that this was a large, well 
phenotyped heart failure cohort with reliable biochemical measurements of 
both insulin and aldosterone in both plasma and urine, allowing accurate 
determination of mineralocorticoid production. 
 
  
CONCLUSIONS 
We have shown that increased aldosterone levels associate with biochemical 
features of insulin resistance in a heart failure population.  This raises the 
possibility that increased insulin resistance could contribute to the adverse 
clinical outcome associated with aldosterone escape in heart failure. This 
hypothesis justifies further investigation in a focussed prospective clinical 
study using gold standard measurements of insulin sensitivity.  
 
 
 
FIGURE LEGENDS 
 
 
Figure 1.  Correlation between early morning fasting insulin and plasma 
aldosterone levels 
 
 
Figure 2. Relationship between (a) fasting insulin (b) HOMA-IR and (c) 
insulin/glucose ratio and plasma and urinary aldosterone 
(Data compared by Mann-Whitney non-parametric testing) 
 
 
Figure 3. Relationship between plasma and urinary aldosterone tertiles  
and fasting plasma insulin. 
Data analysed by one-way ANOVA. 
Plasma aldosterone (pg/ml): tertile 1 34.5-116, tertile 2 119-266. tertile 3 269-
1795 
Urinary aldosterone (mcg/24h); tertile 1 2.65-16.2, tertile 2 16.2-38.2, tertile 3 
38.2-255.2 
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